Gujarat Themis Biosyn Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ff98yqrgkoyiit3z2rrs56gs.pdf

Key Takeaways


Demand & Volume Dynamics

Rajneesh Anand: "The plant is in very good health and the shutdown, which we took last two years, we had taken practically after seven years... So in my view, we will continue to produce through the next year."

Capex Program & Timeline

Sachin Patel: "Our project was going on reasonably well... but within the project we decided to make some modifications because we felt that they would be important for the long-term future of our business. And those modifications essentially led to the delay of a quarter or so, which in a way we expected when we decided this particular call, but we still felt it would be worthwhile the delay considering the capabilities that now we would have in this particular block."

Product & Pipeline Strategy

Sachin Patel: "Fermentation is a tough cookie. We need to move to the next stage which we will be able to only after September once our pilot facilities are ready... I don't think in science I would give a guarantee stamp that everything will work out the way we want to."

Margins & Cost Structure


Balance Sheet & Cash Position


Guidance & Commitments

CommitmentSpecificsTimeline
API block, R&D center, GMP warehouse operationalCapex completed, validation batches beginSeptember 2023
API block revenue contributionFirst commercialization after exhibit batches, stability, and regulatory approvalFY25, or possibly late FY24
Fermentation block operationalLast leg of current capex cycleEnd of calendar year 2024
Production continuityNo plant shutdown planned, continue at full capacityThrough next year (FY24)
Product strategyOnly fermentation-based intermediates, own manufacturing and sales, no job workForeseeable future

Key Metrics

MetricQ4 FY23
Revenue₹28.17 cr, vs ₹28.76 cr in Q4 FY22
EBITDA₹14.93 cr, up 14.12% YoY
EBITDA margin52.98%, up 751 bps YoY; better realizations and lower R&D investment of about ₹3 cr helped margins
PAT₹11.69 cr, vs ₹9.79 cr in Q4 FY22
PAT margin41.50%
EPS₹8.05
FY23 revenue₹148.97 cr, up 29.71% YoY; growth driven by rise in volumes and better realizations
FY23 EBITDA₹74.22 cr, up 27.86% YoY
FY23 EBITDA margin49.82%
FY23 PAT₹57.97 cr, up 32.88% YoY
FY23 PAT margin38.91%
FY23 EPS₹39.90
Total capex plan₹200 cr, spanning over two-plus years
Capex capitalized so far₹16 cr
CWIP₹20 cr
Capital advances for equipment₹10 cr
Fermentation block phase one investment₹80 cr out of ₹200 cr
R&D block cost₹42 cr total: one pilot suite ₹25 cr, two others ₹8 cr, lab ₹9 cr
Additional capex beyond ₹200 cr₹160 cr for two more phases, not yet planned
Production capacity utilization100%, vs 70–75% in the previous year; no plant shutdown taken this year
Q4 other expenses₹1.86 cr, vs ₹4.15 cr QoQ; prior quarter included one-off R&D expenses
Peak quarterly revenue~₹48 cr in Q2 FY23
FY24 revenue growth expectation25% to 30% YoY, implying top line of around ₹190–200 cr (per an analyst's math)
API block expected completionSeptember 2023; commercial sales expected Q1 FY25 after validation and stability
Fermentation block expected completionEnd of calendar year 2024